Aurélia Nguyen, CEPI: "Vaccines will be part of the solution" to the Bundibugyo Ebola outbreak

Aurélia Nguyen, Dep. CEO of CEPI (Coalition of Epidemic Preparedness Innovations) shares her unusual personal and career story, including working with Andrew Witty at GSK, and with Seth Berkley at GAVI during Ebola in West Africa 2014-2015 and later during the COVID-19 pandemic when she managed the COVAX facility. "It was incredibly difficult." CEPI's 3.0 strategy focuses on viral families; technologies and platforms; and networks to rapidly conduct clinical trials and begin manufacturing. CEPI swung rapidly into action with the advent of the Bundibugyo Ebola outbreak in Ituri, DRC. It struck a promising $50 million partnership with the Department of State in support of its work to accelerate development of four vaccine candidates. Clinical trials are beginning and will advance in the fall in the hot zone in eastern DRC. Mistrust and insecurity require intensive community engagement. Even with US and EU support, CEPI still strives to fill an estimated $130 million gap over the next 6-9 months. Her biggest worry? Cases have doubled in just 23 days. We are not yet able to gauge the true scale of the outbreak.